

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **April 2022**

Commission File Number: **001-39034**

**BELLUS HEALTH INC.**

---

*(Name of registrant)*

---

**275 Armand-Frappier Blvd.  
Laval, Québec  
H7V 4A7  
Canada**

---

*(Address of principal executive offices)*

---

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BELLUS Health Inc.**

Date: April 25, 2022

By: /s/ Ramzi Benamar

Name: Ramzi Benamar

Title: Chief Financial Officer

---

## Form 6-K Exhibit Index

Exhibit Number	Document Description
<a href="#">99.1</a>	<a href="#">News Release dated April 25, 2022. BELLUS Health to Participate in Multiple Upcoming Investor Conferences.</a>



**BELLUS Health Inc.**  
275 Armand-Frappier Blvd.  
Laval, Quebec, Canada H7V 4A7

---

## BELLUS Health to Participate in Multiple Upcoming Investor Conferences

LAVAL, Quebec – April 25, 2022 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that the Company’s management team will participate in multiple upcoming investor conferences.

### Presentation Details:

**Event:** 2022 Bloom Burton & Co. Healthcare Investor Conference

**Date/Time:** Monday, May 2<sup>nd</sup>, 2022 at 10:30 a.m. ET

**Format:** In person corporate presentation

**Location:** Toronto, Canada

**Event:** I&I Event hosted by LifeSci Capital

**Date/Time:** Tuesday, May 10<sup>th</sup>, 2022 at 2:30 p.m. ET

**Format:** Virtual fireside chat

**Event:** RBC Capital Markets Global Healthcare Conference

**Date/Time:** Wednesday, May 18<sup>th</sup>, 2022 at 2:35 p.m. ET

**Format:** In person fireside chat

**Location:** New York, NY

**Event:** H.C. Wainwright Global Investment Conference

**Date/Time:** Wednesday, May 25<sup>th</sup>, 2022 at 12:30 p.m. ET

**Format:** In person corporate presentation

**Location:** Miami Beach, FL

Webcasts from the presentations may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health’s website at [www.bellushealth.com](http://www.bellushealth.com). Following the events, archived webcasts will be available on the Company’s website.

### About BELLUS Health ([www.bellushealth.com](http://www.bellushealth.com))

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other cough hypersensitivity indications. The Company’s product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC. BELLUS is planning a Phase 3 program, which is expected to begin in the second half of 2022.

Chronic cough is a cough lasting longer than eight weeks and when the cause of chronic cough cannot be identified or the cough persists despite treatment of all identified associated causes, the condition is referred to as RCC. It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.

---

---

The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

**FOR MORE INFORMATION, PLEASE CONTACT:**

Ramzi Benamar  
Chief Financial Officer  
[rbenamar@bellushealth.com](mailto:rbenamar@bellushealth.com)

**Media:**

Julia Deutsch  
Solebury Trout  
[jdeutsch@soleburytrout.com](mailto:jdeutsch@soleburytrout.com)

Source: BELLUS Health Inc.